Posttranslational modification of p53: cooperative integrators of function.

The p53 protein is modified by as many as 50 individual posttranslational modifications. Many of these occur in response to genotoxic or nongenotoxic stresses and show interdependence, such that one or more modifications can nucleate subsequent events. This interdependent nature suggests a pathway that operates through multiple cooperative events as opposed to distinct functions for individual, isolated modifications. This concept, supported by recent investigations, which provide exquisite detail as to how various modifications mediate precise protein-protein interactions in a cooperative manner, may explain why knockin mice expressing p53 proteins substituted at one or just a few sites of modification typically show only subtle effects on p53 function. The present article focuses on recent, exciting progress and develops the idea that the impact of modification on p53 function is achieved through collective and integrated events.

[1]  Karen H. Vousden,et al.  Modifications of p53: competing for the lysines. , 2009, Current opinion in genetics & development.

[2]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[3]  W. Gu,et al.  FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity* , 2007, Journal of Biological Chemistry.

[4]  A. Strasser,et al.  How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? , 2007, Cell Death and Differentiation.

[5]  A. Fersht,et al.  Interaction between the Transactivation Domain of p53 and PC4 Exemplifies Acidic Activation Domains as Single-stranded DNA Mimics , 2009, The Journal of Biological Chemistry.

[6]  K. Sakaguchi,et al.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53 , 1992, Molecular and cellular biology.

[7]  E. Appella,et al.  SIGNALING TO THE P53 TUMOR SUPPRESSOR THROUGH PATHWAYS ACTIVATED BY GENOTOXIC AND NON-GENOTOXIC STRESSES. , 2002 .

[8]  Xiongbin Lu,et al.  The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. , 2007, Cancer cell.

[9]  Wei Gu,et al.  p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.

[10]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[11]  A. Wlodawer,et al.  Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. , 2009, Biochemistry.

[12]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[13]  Jeffrey R. Marks,et al.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.

[14]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[15]  Shuo Lin,et al.  p53 family in development , 2008, Mechanisms of Development.

[16]  D. Meek,et al.  Protein kinase CK1 is a p53‐threonine 18 kinase which requires prior phosphorylation of serine 15 , 1999, FEBS letters.

[17]  D. Meek,et al.  Mechanisms of switching on p53: a role for covalent modification? , 1999, Oncogene.

[18]  D. Lane,et al.  Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis , 2009, The EMBO journal.

[19]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[20]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[21]  J. Omichinski,et al.  p53 and TFIIEα share a common binding site on the Tfb1/p62 subunit of TFIIH , 2008, Proceedings of the National Academy of Sciences.

[22]  H. K. Sluss,et al.  The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. , 2007, Cancer research.

[23]  W. Gu,et al.  How does SIRT1 affect metabolism, senescence and cancer? , 2009, Nature Reviews Cancer.

[24]  K. Sakaguchi,et al.  Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. , 2008, Journal of molecular biology.

[25]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Y. Miki,et al.  DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. , 2007, Molecular cell.

[27]  K. Yoshikawa,et al.  Necdin Regulates p53 Acetylation via Sirtuin1 to Modulate DNA Damage Response in Cortical Neurons , 2008, The Journal of Neuroscience.

[28]  H. Jane Dyson,et al.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2 , 2009, Proceedings of the National Academy of Sciences.

[29]  Jeffrey S. Smith Human Sir2 and the 'silencing' of p53 activity. , 2002, Trends in cell biology.

[30]  Wei Gu,et al.  SnapShot: p53 Posttranslational Modifications , 2008, Cell.

[31]  T. Iwakuma,et al.  Crippling p53 activities via knock-in mutations in mouse models , 2007, Oncogene.

[32]  S. Berger,et al.  Repression of p53 activity by Smyd2-mediated methylation , 2006, Nature.

[33]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[34]  E. Seto,et al.  The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.

[35]  K. Sakaguchi,et al.  Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation , 1999, The EMBO journal.

[36]  S. Di Giovanni,et al.  The non‐apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon , 2009, EMBO reports.

[37]  K. Vousden,et al.  p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53 , 2008, Cell cycle.

[38]  Or Gozani,et al.  Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.

[39]  S. Sykes,et al.  The ARF/Oncogene Pathway Activates p53 Acetylation within the DNA Binding Domain , 2007, Cell cycle.

[40]  R. Carroll,et al.  Mapping of phosphomonoester and apparent phosphodiester bonds of the oncogene product p53 from simian virus 40-transformed 3T3 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Burlingame,et al.  Identification of New p53 Acetylation Sites in COS-1 Cells* , 2009, Molecular & Cellular Proteomics.

[42]  A. Dejean,et al.  The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. , 2006, Molecular cell.

[43]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[44]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[45]  D. Meek,et al.  Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2 , 1999, The EMBO journal.

[46]  D. Herr,et al.  Ser18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression , 2006, The EMBO journal.

[47]  S. Sykes,et al.  Acetylation of the DNA Binding Domain Regulates Transcription-independent Apoptosis by p53* , 2009, The Journal of Biological Chemistry.

[48]  K. Sakaguchi,et al.  Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase , 2000, The Journal of Biological Chemistry.

[49]  Ettore Appella,et al.  ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation* , 2002, The Journal of Biological Chemistry.

[50]  Danny Reinberg,et al.  Methylation-Acetylation Interplay Activates p53 in Response to DNA Damage , 2007, Molecular and Cellular Biology.

[51]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[52]  D. Meek,et al.  Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. , 2001, The Biochemical journal.

[53]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[54]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[55]  A. Hengstermann,et al.  Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1 , 1999, The EMBO journal.

[56]  Hong Lei,et al.  Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. , 2008, Molecular cell.

[57]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[58]  Maria Miller,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.

[59]  S. Berger,et al.  Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity , 1997, Oncogene.

[60]  Lee Baker,et al.  Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.

[61]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[62]  T. Hupp,et al.  The N-terminal Interferon-binding Domain (IBiD) Homology Domain of p300 Binds to Peptides with Homology to the p53 Transactivation Domain* , 2004, Journal of Biological Chemistry.

[63]  Jill A. Livengood,et al.  p53 Transcriptional Activity Is Mediated through the SRC1-interacting Domain of CBP/p300* , 2002, The Journal of Biological Chemistry.

[64]  M. Fiscella,et al.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[66]  H. K. Sluss,et al.  Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice , 2004, Molecular and Cellular Biology.

[67]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[68]  John Calvin Reed,et al.  Regulation of p53 Localization and Activity by Ubc13 , 2006, Molecular and Cellular Biology.

[69]  R. Hay,et al.  Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation , 2000, Molecular and Cellular Biology.

[70]  W. Gu,et al.  Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity , 2005, Molecular and Cellular Biology.

[71]  Y. Sung,et al.  Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding Protein (*) , 1995, The Journal of Biological Chemistry.

[72]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[73]  Min Gyu Lee,et al.  p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.

[74]  R. Hay,et al.  SUMO‐1 modification activates the transcriptional response of p53 , 1999, The EMBO journal.

[75]  J. Jenkins,et al.  Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53. , 1984, Nucleic acids research.

[76]  Manuel Serrano,et al.  p53: Guardian of the Genome and Policeman of the Oncogenes , 2007, Cell cycle.

[77]  E. Appella,et al.  Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.

[78]  A. Fersht,et al.  Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53 , 2007, Proceedings of the National Academy of Sciences.

[79]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[80]  H. Sheppard,et al.  Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. , 2004, Molecular cell.

[81]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[82]  G. Wahl,et al.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[84]  J. Espinosa,et al.  Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. , 2001, Molecular cell.

[85]  K. Sakaguchi,et al.  SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription. , 2009, Journal of molecular biology.

[86]  S. Durell,et al.  The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. , 2007, Biochemistry.

[87]  A. Thompson,et al.  Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation , 1999, Oncogene.

[88]  A. Aranda-Anzaldo,et al.  Reassessing the role of p53 in cancer and ageing from an evolutionary perspective , 2007, Mechanisms of Ageing and Development.

[89]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[90]  S. Lowe,et al.  E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.

[91]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[92]  G. Kroemer,et al.  Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope , 2005, The Journal of experimental medicine.

[93]  T. Jacks,et al.  Defective apoptosis and B‐cell lymphomas in mice with p53 point mutation at Ser 23 , 2004, The EMBO journal.

[94]  S. Müller,et al.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Yolanda F. Darlington,et al.  The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways , 2008, Cancer and Metastasis Reviews.

[96]  H. Giebler,et al.  Binding of p53 to the KIX Domain of CREB Binding Protein , 1999, The Journal of Biological Chemistry.

[97]  T. Hofmann,et al.  PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. , 2003, Cancer research.

[98]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[99]  Stefano Piccolo,et al.  Integration of TGF-ß and Ras/MAPK Signaling Through p53 Phosphorylation , 2007, Science.

[100]  Albert J. Fornace,et al.  Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase , 2006, The Journal of experimental medicine.

[101]  T. Jacks,et al.  Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. , 2005, Cancer research.

[102]  Yolande F M Ramos,et al.  Comparative study of the p53-mdm2 and p53-MDMX interfaces , 1999, Oncogene.

[103]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[104]  K. Sakaguchi,et al.  Human p53 Is Phosphorylated on Serines 6 and 9 in Response to DNA Damage-inducing Agents* , 2000, The Journal of Biological Chemistry.

[105]  X Chen,et al.  Protein methylation: a new mechanism of p53 tumor suppressor regulation. , 2008, Histology and histopathology.

[106]  T. Hupp,et al.  The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53 , 2003, Molecular and Cellular Biology.

[107]  Yan-Hsiung Wang,et al.  Identification and Characterization of a Novel p300-mediated p53 Acetylation Site, Lysine 305* , 2003, Journal of Biological Chemistry.

[108]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[109]  T. Hofmann,et al.  Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. , 2007, Cancer research.

[110]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[111]  G. Wahl,et al.  Mouse Mutants Reveal that Putative Protein Interaction Sites in the p53 Proline-Rich Domain Are Dispensable for Tumor Suppression , 2006, Molecular and Cellular Biology.

[112]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[113]  Muyang Li,et al.  Acetylation of p53 Inhibits Its Ubiquitination by Mdm2* , 2002, The Journal of Biological Chemistry.

[114]  U. Knippschild,et al.  p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs , 1997, Oncogene.

[115]  C. Maki,et al.  Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination* , 2007, Journal of Biological Chemistry.

[116]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[117]  T. Hupp,et al.  Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300 , 2001, EMBO reports.

[118]  M. Jansson,et al.  Arginine methylation regulates the p53 response , 2008, Nature Cell Biology.

[119]  E. Appella,et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.

[120]  Yoshiharu Kawaguchi,et al.  MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation , 2002, The EMBO journal.

[121]  Ettore Appella,et al.  p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2 , 2001, The EMBO journal.

[122]  Muyang Li,et al.  Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.

[123]  Giulia Piaggio,et al.  Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.

[124]  T. Jacks,et al.  Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389 , 2004, Molecular and Cellular Biology.

[125]  D. Meek,et al.  Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells , 1988, Molecular and cellular biology.

[126]  S. Weger,et al.  Topors acts as a SUMO‐1 E3 ligase for p53 in vitro and in vivo , 2005, FEBS letters.

[127]  Yoichi Taya,et al.  Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.

[128]  H. Dyson,et al.  Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. , 2009, Biochemistry.

[129]  S. Berger,et al.  p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.

[130]  Ronen Marmorstein,et al.  Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.

[131]  D. Meek Tumour suppression by p53: a role for the DNA damage response? , 2009, Nature Reviews Cancer.

[132]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[133]  E. Dennis,et al.  Handbook of cell signaling , 2004 .

[134]  Masaaki Adachi,et al.  p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.

[135]  A. Fersht,et al.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2 , 2009, Oncogene.

[136]  Toshiaki Hara,et al.  Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. , 2006, Molecular cell.

[137]  H. Yasuda,et al.  Involvement of PIAS1 in the sumoylation of tumor suppressor p53. , 2001, Molecular cell.

[138]  J. Qin,et al.  Trim24 targets endogenous p53 for degradation , 2009, Proceedings of the National Academy of Sciences.

[139]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[140]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.